Loading... Please wait...

Blog

CellMosaic, Inc. received Notice of Allowance for AqueaTether™ (AqT™) molecules.

Woburn, MA, Aug. 3, 2016 – CellMosaic announced today that the United States Patent and Trademark Office (USPTO) issued a formal Notice of Allowance for another patent on AqueaTether (AqT™) molecules (Application No. 14/156,224 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). Upon issuance, the patent will provide intellectual property protection for a broad range of [...]

Read More »


CellMosaic Inc. received Notice of Allowance for NeIon™ Technologies.

Woburn, MA, March 24, 2016 – CellMosaic announced today that the United States Patent and Trademark Office (USPTO) issued the Notice of Allowance for all claims filed in Sept. 2015 (Application No. 14/779,805; Trifluoroborate mass spectrometric tags) regarding NeIon™ technologies. The invention provides compositions and methods for mass spectrometry (MS), synthesis, and applications of organo-trifluoroborate as mass tags for use [...]

Read More »


CellMosaic Inc. was awarded a Breast Cancer Research Program Breakthrough Award by the DOD Office of CDMRP

Worcester, MA, March 23, 2015 – CellMosaic Inc. announced today that it has been awarded a Breast Cancer Research Program (BCRP) Breakthrough Award – Funding Level 1 from the Department of Defense (DOD) Office of Congressionally Directed Medical Research Programs (CDMRP) for the development of a target-specific combination drug delivery system within a single molecule (called precision AqT™-warhead) to treat [...]

Read More »


CellMosaic granted first U.S. patent on AqueaTether™ (AqT™) molecules

Worcester, MA, Dec. 10, 2014 – CellMosaic Inc. announced today that the United States Patent and Trademark Office (USPTO) issued its first patent on AqT™ molecules. The newly issued U.S. patent Serial No. 8,907,079 entitled “Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof” describes various AqT™ molecules and architectures based on sugar alcohols. These molecules are used for preparing [...]

Read More »


CellMosaic awarded Phase I SBIR Grant from NIH for development of new technologies for transient molecular complex characterization

Worcester, MA, Sept. 16, 2012 CellMosaic announced today that it has been awarded a Phase I grant from the National Institute of General Medical Sciences (NIGMS) for the development of new technologies for transient molecular complex characterization. With this award, CellMosaic will develop its proprietary oxLink™ crosslinking reagent kit-method-software package for the identification and quantitation of [...]

Read More »